Granted Patent
B2
US 10,538,555 · App. 15/510,138 · Granted Jan 21, 2020
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
Inventors:
Michael Matthew Miller (Lambertville, NJ); Claudio Mapelli (Langhorne, PA); Martin Patrick Allen (Flemington, NJ); Michael S. Bowsher (Prospect, CT); Eric P. Gillis (Cheshire, CT); David R. Langley (Meriden, CT); Eric Mull (Guilford, CT); Maude A. Poirier (Pennington, NJ); Nishith Sanghvi (Bridgewater, NJ); Li-Qiang Sun (Glastonbury, CT); Daniel J. Tenney (Yardley, PA); Kap-Sun Yeung (Madison, CT); Juliang Zhu (North Haven, CT); Kevin W. Gillman (Madison, CT); Qian Zhao (Wallingford, CT); Katharine A. Grant-Young (Madison, CT); Paul Michael Scola (Glastonbury, CT); Lyndon A. M. Cornelius (Jackson, NJ)
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Claims (4)
1. A compound selected from
or a pharmaceutically acceptable salt thereof.
2. A method of treating septic shock in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 .
3. A method blocking the interaction of PD-L1 with PD-1 and/or CD80 in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 .
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 7, 2019
From: MILLER, MICHAEL MATTHEW; MAPELLI, CLAUDIO; ALLEN, MARTIN PATRICK; BOWSHER, MICHAEL S.; GILLIS, ERIC P.; LANGLEY, DAVID R.; MULL, ERIC; POIRIER, MAUDE A.; SANGHVI, NISHITH; SUN, LI-QIANG; TENNEY, DANIEL J.; YEUNG, KAP-SUN; ZHU, JULIANG; GILLMAN, KEVIN W.; ZHAO, QIAN; GRANT-YOUNG, KATHARINE A.; SCOLA, PAUL MICHAEL; CORNELIUS, LYNDON A.M.
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 049993/0450 →
Continuity (1)
Cited By (2)